Compounded tirzepatide with NAD+ and L-carnitine is a multi-ingredient formulation combining a dual GIP/GLP-1 receptor agonist with nicotinamide adenine dinucleotide and levocarnitine in a single preparation. Compounding pharmacies prepare it when a prescriber documents a patient-specific clinical need that an FDA-approved product cannot meet.
This two-additive combination carries the highest regulatory scrutiny of any GLP-1 preparation covered here: each added ingredient must stand on its own documented clinical rationale, and multi-ingredient combinations face more regulatory questions than any single-agent or single-additive GLP-1 formulation.
September 2026 Enforcement Update
On September 18, 2026 the FDA issued a warning letter to Empower Pharmacy, one of the largest compounders of GLP-1 products, concluding that its tirzepatide/niacinamide and semaglutide/cyanocobalamin (B12) products remained essentially copies of the approved drugs despite the added ingredient. The reasoning applies with extra force to a two-additive product: each added ingredient needs its own patient-specific justification, and neither takes the product outside the copy analysis by itself. Three points from the letter apply directly:
- Volume is evidence. The FDA said the volume being produced suggested the claimed differences from the approved products were pretextual. Scale now counts against a formulation on its own, independent of the paperwork behind it.
- Templates fail. The agency flagged boilerplate significant-difference language and prescriptions with no determination at all.
- Platforms are in scope. The letter pointed to third-party platforms that offer prescribers pre-selected options.
This follows the FDA's April 1, 2026 clarification, which used semaglutide plus vitamin B12 as its example of a product it may treat as essentially a copy when the route matches and the strengths are within 10% of the commercial products. The sections below were updated in October 2026 to reflect both. For the full analysis, see FDA's September 2026 warning letter to Empower: what it means for clinics.
What Tirzepatide, NAD+, and L-Carnitine Are
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Through those two incretin pathways it influences insulin secretion, gastric emptying, and appetite signaling. The molecule is the active ingredient in FDA-approved branded products indicated for type 2 diabetes and for chronic weight management in adults meeting labeled criteria.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, involved in redox reactions and cellular energy metabolism. It is not an FDA-approved drug. Longevity, wellness, and metabolic practices order it on the basis of cellular-energy and metabolic rationales.
L-carnitine (levocarnitine) is a compound involved in the transport of long-chain fatty acids into mitochondria for beta-oxidation. FDA-approved levocarnitine products exist for specific indications such as primary and secondary carnitine deficiency; use as a general metabolic additive in a compounded GLP-1 preparation falls outside those approved indications.
Combining all three in one preparation means a single injection delivers an incretin agonist alongside two metabolic cofactors. The regulatory implication is straightforward: each of the three components carries its own status and its own justification burden.
How Providers Use It in Practice
Clinics that order compounded tirzepatide with NAD+ and L-carnitine are typically in the weight-management and metabolic space, including medical weight-loss practices, longevity and wellness clinics, and some primary-care and endocrinology-adjacent settings. The combination is generally positioned within a broader metabolic or body-composition program rather than as a standalone therapy.
Convenience and adherence — fewer separate injections — are not a significant clinical difference under the essentially-a-copy framework, and the FDA's September 2026 warning letter treated consolidation-style rationales applied across a panel as pretextual. The additives have not been studied in combination with tirzepatide in the controlled trials that supported the branded product's approval, and combining them does not confer the efficacy or safety profile of any FDA-approved drug. A prescriber who chooses this combination takes on responsibility for a documented, patient-specific clinical reason for each component.
Because this formulation stacks two additives, it tends to draw more scrutiny than single-agent or single-additive GLP-1 variants. A prescriber choosing it should be prepared to articulate, per patient, why NAD+ is indicated and, separately, why L-carnitine is indicated, in addition to the tirzepatide rationale itself.
Forms and Combinations Available Through Compounding
Compounded tirzepatide combinations are most commonly prepared as sterile injectables for subcutaneous administration. The rationale for compounding a multi-ingredient product is patient-specific customization: a licensed prescriber determines that an individual patient requires a formulation the manufactured product does not provide, and a licensed pharmacy prepares it to that specification.
Related formulations in this category include:
- Single-agent compounded tirzepatide.
- Tirzepatide with a single vitamin additive, such as compounded tirzepatide with B6.
- Tirzepatide with L-carnitine alone, covered in compounded tirzepatide with L-carnitine.
- Standalone compounded NAD+, ordered by longevity and wellness practices.
This article intentionally omits strengths, dosing, and titration. Those are individualized clinical decisions made by the prescriber and the dispensing pharmacist, not content for an educational overview.
Regulatory Status and Provider Considerations
The regulatory picture for compounded tirzepatide changed materially over the past two years, and the two-additive combination sits at the sharpest end of it.
The shortage is resolved. FDA determined the tirzepatide shortage resolved and re-affirmed that determination on December 19, 2024. The agency set transition periods during which it did not intend to take enforcement action against compounders producing copies of the branded product: 503A pharmacies through March 5, 2025 (first set for February 18 and extended pending a court ruling), and 503B outsourcing facilities through March 19, 2025 (as of November 2026). With the shortage over, tirzepatide is no longer eligible for compounding on shortage grounds.
The "essentially a copy" framework now governs. Outside a shortage, a 503A pharmacy compounding a drug that is essentially a copy of a commercially available FDA-approved product must document a patient-specific clinical difference — a change that produces a significant difference for that individual patient, as determined by the prescriber. A combination product may be argued to be more than a copy because it contains additional active ingredients, but that argument does not remove the underlying obligation to justify the formulation; FDA has questioned whether blanket additive rationales meet the individualized-need standard.
Additives require individualized justification — twice here. FDA has said that the safety and effectiveness of adding ingredients such as B vitamins to GLP-1 drugs have not been established, and neither NAD+ nor L-carnitine was part of the trials that supported the branded tirzepatide products. The responsibility to justify each additive on a patient-specific basis rests with the prescriber. Because this preparation contains two additives, that burden applies independently to NAD+ and to L-carnitine. This is the plain reason multi-ingredient GLP-1 combinations tend to face more regulatory questions than single-agent or single-additive formulations.
Proposed exclusion from the 503B bulks list. On May 1, 2026, FDA published a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these substances from bulk. The comment period, extended to July 30, 2026, has closed, and no final decision had been published as of November 2026. Outsourcing facilities already cannot compound tirzepatide from bulk, because it is on neither the 503B bulks list nor the FDA drug shortage list; a final exclusion would keep it that way outside a future shortage.
Nothing here should be read to suggest compounded tirzepatide combinations are FDA-approved or equivalent to any branded product. They are not. Compounded drugs are not FDA-approved, are not reviewed by FDA for safety and efficacy before marketing, and do not carry the manufactured product's approval. The compliance judgment for each prescription remains with the prescriber and pharmacist.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because this is a sterile, multi-ingredient injectable, sourcing diligence matters more, not less. Questions worth asking any pharmacy before ordering:
- API source and Certificates of Analysis. Request the source of the tirzepatide active pharmaceutical ingredient and CoAs for each component, including NAD+ and levocarnitine.
- USP compliance. Confirm adherence to USP <795> (non-sterile compounding), <797> (sterile compounding), and <800> (hazardous drugs) as applicable to the preparation.
- Potency and sterility testing. Ask about potency assays, sterility testing, and endotoxin testing on the finished multi-ingredient product — not just the individual inputs.
- Beyond-use dating. Understand the assigned beyond-use date and the stability data supporting it for the specific combination, since combining ingredients can affect stability.
- State licensure. Verify the pharmacy's licensure in the states where it dispenses. Compounded tirzepatide is a patient-specific 503A prescription; 503B outsourcing facilities cannot compound it from bulk.
- Compatibility rationale. For a two-additive product, ask what data or references support physical and chemical compatibility of tirzepatide with both NAD+ and L-carnitine in a single preparation.
Frequently Asked Questions
Is compounded tirzepatide with NAD+ and L-carnitine FDA-approved?
No. No compounded drug is FDA-approved. The branded tirzepatide products are FDA-approved for their labeled indications, but a compounded multi-ingredient preparation is not reviewed or approved by FDA and is not equivalent to any manufactured product.
Why does this combination draw more regulatory scrutiny than single-additive tirzepatide?
Because it stacks two additives. Each added ingredient — NAD+ and L-carnitine — needs its own documented, patient-specific clinical rationale, on top of the justification for the tirzepatide itself. FDA has questioned blanket additive rationales, so more components mean more questions.
Can pharmacies still compound tirzepatide now that the shortage is resolved?
The shortage-based pathway closed after the 2024 resolution and the early-2025 transition periods. Outside a shortage, compounding is governed by the essentially-a-copy framework, which for 503A pharmacies requires a documented patient-specific clinical difference. 503B outsourcing facilities cannot compound tirzepatide from bulk, and a May 2026 FDA proposal would keep it that way.
Who is responsible for justifying the additives?
The prescriber. The individualized clinical need for each ingredient is the prescriber's documented determination, and the dispensing pharmacist shares responsibility for compounding within applicable rules.
Related Reading
Sources
- FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- FDA: Declaratory Order — Resolution of Shortages of Tirzepatide Injection
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B — Extension of Comment Period (June 26, 2026)
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
- FDA: Warning Letters (search "Empower Clinic Services", September 18, 2026)
- Frier Levitt: FDA Warning Letter Targets Compounded GLP-1 Products (September 2026)